Kornimate/medical-research-clean huggingface dataset:
quality of life after tension free transvaginal sling / tape operation with a titanized surgical tape (tiloop® tape)

Conditions: Urinary Incontinence, Stress

Summary: validation of a new quality of life (qol) questionnaire in a population of patient gaining a tiloop® tape surgical mesh for stabilization of the urethra.

the prevalence of urinary incontinence in the adult female population has been estimated between 10% and 40%. several treatment alternatives have been suggested until now. nevertheless, the ideal treatment has not been identified yet. on the one hand this is related to the low amount of valid scientific information regarding different treatment methods. on the other hand the impact of patients' quality of life, which plays a major role, has not been fully considered. to date, there is no established questionnaire on quality of life that provides physicians an assistance to obtain information on the subjective effects caused by stress urinary incontinence. in the present study the patients' quality of life will be assessed by use of two questionnaires, that is a new one and an already validated questionnaire. the study population consists of patients who already received an implantation of a sub-urethral surgical mesh (tiloop® tape), of symptomatic patients before an operation, and of a group of non-symptomatic women. subjects will be asked in a single visit only to fill in both questionnaires. furthermore the safety and effectiveness of the tiloop® tape mesh will be evaluated in the study arm of treated patients. study has been terminated after major recruitment failure (only 21 instead of 240 patients has been included).

Eligibility criteria:
inclusion criteria: * depending on study arm: * women with a tiloop® tape implant, implanted between 2007 and 2009 at the study center - or - * woman with a planned tape implantation at the study center - or - * woman with no disease related to incontinence * subject is able to understand the nature, relevance and significance of the clinical trial * subject has given informed consent exclusion criteria: * subject revoked consent * lack of subject's compliance regarding data collection or examination in the scope of the trial (non-compliance) * subject institutionalized by court or official order (mpg §20.3) * subject participates in another clinical investigation

Keywords: sub-urethral sling treatment outcome quality of life
study to justify steroid use in preterm neonates to prevent bronchopulmonary dysplasia

Conditions: Bronchopulmonary Dysplasia

Summary: most preterm babies require supplemental oxygen for a variable period of time, up to several weeks or months after birth. the aim of oxygen therapy is to achieve adequate oxygen supply to the tissues without causing oxygen toxicity and oxidative stress. the current routine monitoring relies on oxygen saturation by pulse oximetry without identifying the underlying pathology, as lung parenchyma and pulmonary vascular disease can be contributed in pathophysiology at variable degrees. steroids usage for prevention of bronchopulmonary dysplasia also has been shown to have adverse neurodevelopmental outcome. available data are conflicting and inconclusive; clinicians must use their own clinical judgment to balance the adverse effects of bronchopulmonary dysplasia with the potential adverse effects of treatments for each individual patient. very low birth weight infants who remain on mechanical ventilation after 1 to 2 weeks of age are at very high risk of developing bronchopulmonary dysplasia. when considering corticosteroid therapy for such an infant, clinicians might conclude that the risks of a short course of glucocorticoid therapy to prevent bronchopulmonary dysplasia are warranted.

this is a prospective study. 30 preterm infants admitted to neonatal intensive care units of maadi, ghamra military hospitals, and ain shams university hospitals, will be prospectively enrolled within 24 hours after birth. daily evaluation of oxygen histograms with measurement of the cumulative time of oxygen saturations below 80%, (risk of hypoxemia and potential tissue hypoxia), and arterial oxygen saturations sao2 above 95% (potential risk of hyperoxia and increased oxidative stress). evaluation window will be on a weekly basis as long as the infant is on oxygen support and by applying oxygen tolerance test. the treating clinical team will be blinded to all results of oxygen tolerance test.

Eligibility criteria:
all preterm neonates admitted to the neonatal intensive care unit will be considered eligible for inclusion. fully informed written consent from parents of all eligible infants will be sought prior to enrollment. infants with major congenital abnormalities, cardiac lesions other than patent ductus arteriosus, and lung hypoplasia will be excluded from this study. inclusion criteria: * \< 36 week gestation pre-terms, not having major congenital anomalies exclusion criteria: * congenital heart disease * major congenital abnormalities
carotid ultrasound sub-study of the familial atherosclerosis study-observational study

Conditions: Carotid Stenosis

Summary: this observational study looks at carotid stenosis in two groups of subjects using a non-invasive procedure, b-mode ultrasound. one group of subjects has had long-term intensive lipid altering therapy (lowering ldl-c plus raising hdl-c). the second group of patients has been on conventional "standard of care" treatment for carotid stenosis. the study will look at the carotid intima-media thickness (cmit) in both groups. hypothesis: cimt will differ between the two groups, such that the cimt will be less in the subjects on intensive lipid altering therapy.


Eligibility criteria:
inclusion criteria: * intensive lipid-lowering therapy group: subjects currently enrolled in the familial atherosclerosis treatment observational study. * usual care group: subjects who were in the fats os study in the past, but have since quit the study and opted for conventional "standard of treatment". exclusion criteria: * no past or present participation in the fats os study.
yf476 and type i gastric carcinoids (norway)

Conditions: Chronic Atrophic Gastritis; Hypergastrinemia; Type I Gastric Carcinoids

Summary: the aim of the study is to find out if the experimental medicine, yf476, can make gastric carcinoids, a rare type of stomach tumour, shrink and disappear. gastric carcinoids occur mainly in patients with chronic atrophic gastritis (cag), a condition in which the acid-producing cells in the lining of the stomach can't make acid. acid production is controlled by gastrin, a hormone (chemical messenger) that's released into the bloodstream. if the stomach can't make acid, blood levels of gastrin rise. high blood levels of gastrin in patients with cag can cause other cells (ecl cells) in the lining of the stomach to grow and, over the years, to give rise to gastric carcinoids. gastric carcinoids are usually benign, but they can become malignant. therefore, patients with cag and gastric carcinoids have the inside of their stomach checked regularly, by gastroscopy, to see if the gastric carcinoids need removing surgically. a gastroscope is a thin (1 cm), flexible tube at end of which is a mini video camera, which enables the user to inspect the lining of the stomach and a 'snare' to take samples of tissue (biopsies). yf476 (netazepide) is a gastrin receptor antagonist (blocks the effects of gastrin), so it's a potential new medical treatment for gastric carcinoids in patients with cag. up to 10 of these patients will take yf476 daily for up to 12 weeks. they'll make up to seven outpatient visits for tests, including checks on the safety of yf476 and up to four gastroscopies. at each gastroscopy, the gastric carcinoids will be measured and biopsies taken for laboratory tests. patients will take up to 24 weeks to finish the study.


Eligibility criteria:
inclusion criteria: * patients known to have gastric carcinoids associated with chronic atrophic gastritis and hypergastrinaemia, and who attend the outpatient clinic of the investigator; * men, postmenopausal women, premenopausal women who have been sterilised by tubal ligation, hysterectomy or bilateral oophorectomy, or premenopausal women using reliable contraception: condom and spermicide or intrauterine device; * adults ≥ 18 years; * good general health; and * able to give fully-informed, written consent. exclusion criteria: * women who are pregnant, lactating or using a steroid contraceptive; * history of gastric surgery, apart from surgery for gastric carcinoids; * evidence of zollinger-ellison syndrome; * prolonged qtc interval (\>450 msec); * certain medicines and herbal remedies taken during the 7 days before visit 1; * previous treatment with somatostatin; or * participation in other clinical trials of unlicensed medicines within the previous 3 months.

Keywords: yf476 netazepide hypergastrinaemia gastric carcinoids
the effect of clomiphene citrate plus estradiol valerate versus letrozole on endometrial thickness and pregnancy rate in infertile women

Conditions: Endometrial Thickness; Pregnancy Rate

Summary: the present randomized double blind study has been carried out in gynecology and obstetrics department, faculty of medicine, zagazig university on 70 women were previously received clomiphene citrate alone as management of infertile anovulatory pcos women, but giving improper endometrial thickness \< 7mm during the period from march 2019 to september 2019

polycystic ovarian syndrome (pcos) is the most common endocrine disorder in infertile women. infertility affects 40% of women with pcos. understanding the main causes of infertility and selecting an appropriate treatment plan is a diagnostic and therapeutic priority the aim of this work was to compare the effect of clomiphene citrate plus estradiol valerate versus letrozole on endometrial thickness and pregnancy rate in infertile pcos women underwent ovulation induction the study was designed as a randomized double blind study using a computer-generated randomization list and sequentially numbered opaque sealed envelopes, each containing the allocation information written on a card. envelopes were opened sequentially by a study nurse to allocate patients to the assigned group. these patients were divided into two groups: 1. group a (clomiphene citrate \& estradiol group): included 35 anovulatory pco patients who received clomiphene citrate (clomid; aventis pharma s.ae, global napi pharmaceuticals, cairo, egypt) 100 mg daily from cycle day 3 to 7 with estradiol valerate 4-mg (two white tablets of cyclopregynova) from cycle day 8 to 14. 2. group b (letrozole group): included 35 anovulatory pco patients who received letrozole (femara; novartis pharma ag, basle, switzerland) 5 mg daily from cycle day 3 to day 7.

Eligibility criteria:
inclusion criteria: * patients aged 18-35 years old with complete infertility workup * patients diagnosed as having pcos women * normal semen analysis exclusion criteria: * patients with male factor infertility, hyperprolactinemia, thyroid disorder. * patients with any tubal pathology or uterine pathology. * contraindication of ovulation induction, (multiple ovarian cysts or allergy to inducing agent "clomid"). * known or suspected pelvic infection (pid).

Keywords: letrozole clomiphene citrate pcos endometrial thickness
the relationship between upper extremity exercise capacity, respiratory and peripheral muscle strength in chronic low back pain

Conditions: Chronic Low Back Pain

Summary: the aim of the study was to evaluate the upper extremity exercise capacity of individuals with chronic low back pain and to investigate its relationship with respiratory muscle strength, peripheral muscle strength, chest expansion, pain, disability level, fear of movement and quality of life.


Eligibility criteria:
inclusion criteria: * voluntary participation in the study * being aged 18-65 * chronic low back pain for at least the last 3 months * pain intensity according to visual analogue scale (vas) ≥3 exclusion criteria: * history of cancer * presence of spinal infection * presence of rheumatological disorders * presence of spinal fracture * red flag signs * having a psychological disorder * presence of spinal surgery * having radiculopathy * presence of anatomical and congenital abnormalities
solutions for atrial fibrillation edvocacy (safe)

Conditions: Cardiovascular Diseases; Cardiac Arrhythmia; Atrial Fibrillation

Summary: the aim of this demonstration project is to create an additional access point in the community at local pharmacies for atrial fibrillation screening, detection, and referral to physicians for follow-up and initiation of evidence-based therapy when appropriate.

the apha foundation will implement the solutions for atrial fibrillation edvocacy (safe) demonstration project integrating atrial fibrillation (afib) screening, detection, and referral services as a routine component of care in community-based pharmacies. the safe solution is designed to improve awareness about afib, increase access to screening and education opportunities related to afib, and offer a team-based approach to care that will ultimately improve public health outcomes. this multi-site study will utilize community pharmacies to identify patients at-risk for afib through point-of-care patient encounters, proactive patient profile reviews, risk assessment tools, and alivecor's fda-cleared ekg technology. as part of their usual and customary care, pharmacists can identify patients potentially at-risk for afib through routine patient encounters, proactive patient profile reviews, and subsequent discussions with the patient. identified patients will then be asked to complete a stroke risk assessment which will help determine the patient's risk level. the pharmacist will utilize the results from the stroke risk assessment to educate the patient on why these factors could add risk, why it's important to monitor these factors, and how the patient can work to reduce or improve upon certain modifiable risk factors. all patients will be educated about the risks of afib and the importance of future monitoring based on their risk level. patients will then be offered the opportunity to utilize the alivecor ekg technology to capture an ekg reading at the point-of-care. this fda-cleared device is easy for patients to use and a pharmacy team member will be available to guide the patient to ensure proper use. patients who are identified as having an abnormal heart rhythm, based on their ekg reading, will be referred to their physician for evaluation and follow-up. pharmacists will follow-up with the patients that were referred to the physician to facilitate the transition of care and inquire about confirmation of afib and initiation of treatment. coordination and communication among patients, pharmacists, and physicians is the foundation of this patient-centered team-based care approach.

Eligibility criteria:
inclusion criteria: * any person at least 18 years of age * person who is able to present to a pharmacist for usual and customary care exclusion criteria: * persons who are pregnant * persons who are lacking in capacity * persons who have a pacemaker or implantable cardioverter defibrillator (icd) or other implanted electronic devices
effects of spironolactone combination therapy on proteinuria, kidney function, and blood pressure

Conditions: Type 2 Diabetes Mellitus; Diabetic Nephropathy; Essential Hypertension

Summary: the detrimental effects of aldostrone are not adequately arrested by the use of angiotensin converting enzyme (ace), angiotensin ii receptor blocker (arb) or a combination of both. recent evidence has provided robust evidence that aldostrone escape plays an important role in this regard. it is believed that aldostrone escape occurs quite commonly with reports indicating prevalence rates as high as 22% with arbs and 40% with ace inhibitors. in a trial of patients with diabetes and hypertension it was shown that treatment of aldostrone escape with spironolactone 25 mg daily for three months significantly reduces proteinuria. a number of other trials have similarly observed that addition of spironolactone to an ace inhibitor based regimen provides additional benefits on proteinuria reduction, blood pressure control, and prevention of glomerular filtration rate (gfr) decline. most of the available trials in this regard are of short duration (e.g. three months), and have added spironolactone to an ace or ace+arb based regimen (the so-called triple blockade). currently, evidence evaluating efficacy of a combined arb+spironolactone regimen compared with conventional double ras blockade (i.e. ace+arb) is lacking. hence, this randomized open label trial was initiated to determine the effects of addition of spironolactone 25 mg daily to losartan over a period of 18 months.


Eligibility criteria:
inclusion criteria: * type 2 diabetes patients with diabetic nephropathy in the range of micro- or macroalbuminuria * treatment with combination of enalapril and losartan for more than one year exclusion criteria: * history of non-adherence to prescribed medication assessed by the prescribing physician * baseline potassium \> 5.5 meq/l * chronic kidney disease stages 4 or 5 * history or evidence of non-diabetic kidney disease
pilates with blood flow restriction for improving strength, balance, and cognition in older adults

Conditions: Blood Flow Restriction Exercise; Resistance Training; Elderly (People Aged 65 or More); Muscle Strength; Balance; Cognition; Depression

Summary: this study aims to examine the effects of pilates exercise with a blood flow restriction cuff on muscle strength, balance, physical performance, depression, and cognitive function in community-dwelling older adults.

this randomized controlled trial investigates the effects of pilates exercise combined with blood flow restriction (bfr) in community-dwelling older adults. a total of 26 participants aged 65 and older will be randomly assigned to either a bfr pilates group or a control group that performs the same pilates exercises without bfr. the intervention will be conducted twice a week for 8 weeks (16 sessions total). the bfr cuffs will be applied at 50% of the participant's arterial occlusion pressure. both groups will undergo the same pilates protocol, supervised by trained personnel. assessments will be performed at baseline and after the intervention. primary outcome measures include lower limb strength (5 times sit-to-stand test), balance ability (timed up and go test, good balance system), gait performance (10-meter walk test, gaitrite), muscle mass index (smi) using bwa 2.0 and handgrip strength, muscle thickness (quadriceps via ultrasound and calf circumference), cognitive function (moca), depression level (gds-k), and fall efficacy (k-fes-i). both participants and outcome assessors are blinded to group allocation. this study has received irb approval from sahmyook university institutional review board.

Eligibility criteria:
inclusion criteria: 1. community-dwelling individuals aged 65 years and older who have not had a fall in the past year. 2. no neurological or musculoskeletal condition that would interfere with exercise performance. 3. clear consciousness and able to communicate effectively. 4. capable of reading and writing. 5. able to understand the research explanation and provide informed consent. exclusion criteria: 1. orthopedic, neurological, or vascular conditions that may affect vital signs such as dizziness, blood pressure instability, or fall risk during assessment. 2. any history of musculoskeletal surgery within the past 6 months. 3. physician-determined health status that contraindicates exercise participation. 4. cognitive or literacy impairments that hinder understanding of study procedures.

Keywords: blood flow restriction training older adults muscle mass functional mobility cognition
effects of early stepping verticalization + fes on cip

Conditions: Critical Illness Polyneuropathy; Acquired Brain Injury

Summary: background: intensive care unit (icu) survivors often develop an acquired weakness due to a critical illness polyneuropathy (cip). early mobilization in icu, by reducing the bed rest and decreasing the oxidative stress, was shown to represent a valid preventive option. purpose: to evaluate whether icu sessions of stepping verticalization associated with functional electrical stimulation (fes) of the lower limbs are able to reduce the occurrence of cip in acquired brain injured (abi) patients. methods: all the abi patients admitted in our neurorehabilitation unit from our icu were retrospectively evaluated. patients affected by previous peripheral neuropathy, diabetes, cancer, alcoholism, viral hepatitis, aids and autoimmune diseases were excluded. they were divided into 3 groups according to the rehabilitation strategy received in icu: group 1 received conventional physiotherapy + stepping verticalization sessions with erigo® (hocoma, switzerland); group 2 received conventional physiotherapy + stepping verticalization sessions with fes using erigopro®; group 3 received only conventional physiotherapy. as for internal protocol, all patients started rehabilitation in the first week from the abi and performed 60 minutes/day of rehabilitation, 5 days/week. primary outcome was the evidence of cip at neurorehabilitation admission (=icu discharge), according to neurophysiological criteria. secondary outcomes were the strength impairment at neurorehabilitation discharge, measured by the total motricity index score and the functional ambulation classification (fac) score, assessing quality of gait.


Eligibility criteria:
inclusion criteria: * arriving directly from our acute care facility * hospitalized in icu due to an acute brain injury exclusion criteria: * previous peripheral neuropathies * diabetes * cancer * alcoholism * viral hepatitis * aids * autoimmune diseases * absence of clinical or neurophysiological informations at data collection